Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate.

@article{Boerman1999PretargetingOR,
  title={Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate.},
  author={Otto C Boerman and Marion H. G. C. Kranenborg and Egbert Oosterwijk and Gary L. Griffiths and William J H Mcbride and Wim J. C. Oyen and Mirjam C.A. de Weijert and Jeannette C. Oosterwijk-Wakka and H. J. Hansen and Frans H. M. Corstens},
  journal={Cancer research},
  year={1999},
  volume={59 17},
  pages={4400-5}
}
Radiolabeled monoclonal antibodies (mAbs) can target tumors selectively. Sustained activity levels in nontarget tissues limit their application. Pretargeting approaches using bispecific mAbs (bsmAbs) or the biotinavidin interaction have been proposed to improve tumor:nontumor ratios. Pretargeting a tumor and subsequently administering the radioactivity as a low molecular weight ligand fundamentally changes the pharmacokinetics of the radiolabel. In previous studies, we have shown successful… CONTINUE READING